|
Market Closed -
Saudi Arabian S.E.
08:20:00 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 66.85 SAR | +0.22% |
|
+3.24% | +5.20% |
| 08-27 | Avalon Pharma Reiterated at Overweight as Aljazira Capital Notes 'Solid' Q2 Growth | MT |
| 08-20 | Avalon Pharma Renews SAR50 Million Credit Facility | MT |
Company Valuation: Middle East Pharmaceutical Industries Company
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
| Market Cap 1 | 2,436 | 2,224 |
| Change | - | -8.7% |
| Enterprise Value (EV) 1 | 2,479 | 2,253 |
| Change | - | -9.09% |
| P/E | 30.5x | 22.9x |
| PBR | 6.62x | 5.34x |
| PEG | 1.4x | 1.1x |
| Capitalization / Revenue | 6.18x | 4.83x |
| EV / Revenue | 6.29x | 4.89x |
| EV / EBITDA | 25x | 18.9x |
| EV / EBIT | 27.8x | 21.1x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Dividend per Share 2 | 1.143 | 1.383 |
| Rate of return | 1.64% | 2.18% |
| EPS 2 | 2.281 | 2.772 |
| Distribution rate | 50.1% | 49.9% |
| Net sales 1 | 394 | 460.5 |
| EBITDA 1 | 99.08 | 119.1 |
| EBIT 1 | 89.29 | 106.9 |
| Net income 1 | 79.85 | 97.01 |
| Net Debt 1 | 42.83 | 29.47 |
| Reference price 2 | 69.60 | 63.54 |
| Nbr of stocks (in thousands) | 35,000 | 35,000 |
| Announcement Date | 3/27/25 | 3/8/26 |
1SAR in Million2SAR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 623M | |
| 35.04x | 6.58x | 22.81x | 0.9% | 48.26B | |
| 17.32x | 2.17x | 9.78x | 1.49% | 40.5B | |
| 26.96x | 3.27x | 16.93x | 0.94% | 11.85B | |
| 26.85x | 3.84x | 15.92x | 0.6% | 11.83B | |
| 19.17x | 3.41x | 11.88x | 3.76% | 9.36B | |
| 9.39x | 2.16x | 5.58x | 4.61% | 7.5B | |
| 15.79x | 2.07x | 6.88x | 3.19% | 7.37B | |
| 29.64x | 3.88x | 18.04x | 0.16% | 7.28B | |
| Average | 22.52x | 3.42x | 13.48x | 1.96% | 16.06B | |
| Weighted average by Cap. | 25.09x | 4.04x | 15.43x | 1.51% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4016 Stock
- Valuation Middle East Pharmaceutical Industries Company
Select your edition
All financial news and data tailored to specific country editions
